Akari Therapeutics, Plc (AKTX)
Akari Therapeutics, Plc operates in the Biotechnology industry of the Healthcare sector, headquartered in Tampa, FL, US. The stock last traded at $7.25, down 6.27% on the session, giving a market capitalisation of $8.3M. On trailing twelve-month figures it carries a trailing P/E of -0.01, a net margin of 0.0%. Its beta of 1.39 implies it has historically moved more than the broad market.
Akari Therapeutics, Plc, an oncology company, develops antibody-drug conjugates (ADC) for cancer-killing toxins. Its lead payload is PH1 to disrupt the function of spliceosomes and to trigger an immune response that leads to additional cancer cell killing. The company’s lead product candidate is AKTX-101, a preclinical stage trop2-targeting ADC that combines PH1 with the trop2 antibody to treat solid tumor cancer types, including lung, breast, bladder, head and neck, gastric, pancreatic, colon, prostate, and others. Its payloads include PH1 is a novel payload that is a spliceosome modulator designed to disrupt RNA splicing within cancer cells. The company also develops AKTX-102, a novel bispecific ADC that utilizes PH1 as its payload to treat various solid tumor cancers. Akari Therapeutics, Plc is headquartered in Tampa, Florida.
Akari Therapeutics, Plc is most often compared with the following Healthcare names: